Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS- mutated non-small cell lung cancer with STK11 , KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial.

Howard Jack WestMark McClelandFederico CappuzzoMartin ReckTony Sk MokRobert M JotteMakoto NishioEugene KimStefanie MorrisWei ZouDavid ShamesMeghna Das ThakurGeetha ShankarMark A Socinski

Published in: Journal for immunotherapy of cancer (2022)

mutations and/or high PD-L1 expression.

Keyphrases

phase iii
open label
wild type
clinical trial
phase ii
double blind
placebo controlled
locally advanced
metastatic colorectal cancer
protein protein
study protocol
radiation therapy
squamous cell carcinoma
rectal cancer